Skip to main content

Market Overview

Analyst: Chimerix Govt. Smallpox Pact Worth Up To $435 Million

Share:

Chimerix Inc (NASDAQ: CMRX)'s proposed government contract to produce up to 1.7 million doses of a treatment for smallpox could be worth up to $435 million, an analyst said Wednesday.

The company was awarded the sole-source, five-year contract Monday, although it would formally receive it until April 28 to verify that no other sources can supply the drug.

"It's Chimerix's contract for the taking," according to Brean's Jonathan Aschoff who maintained a Buy rating and $45 target.

Chimerix has 2014 revenue of $4 million.

Chimerix has been working with the agency, the Biomedical Advanced Research and Development Authority, or Barda, since 2011 on developing its brincidofovir drug as a treatment for both smallpox as well as for cytomegalovirus, which is dangerous to newborn children.

Barda, an arm of the U.S. Department of Health and Human Services, said a data package to support a new drug application for brincidofovir for the prevention of CMV is nearing completion.

Chimerix gained more than 3 percent since obtaining the contract and closed Wednesday at $38.26, down $0.39.

Latest Ratings for CMRX

DateFirmActionFromTo
Dec 2021HC Wainwright & Co.MaintainsBuy
Nov 2021HC Wainwright & Co.MaintainsBuy
Jun 2021HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for CMRX

View the Latest Analyst Ratings

 

Related Articles (CMRX)

View Comments and Join the Discussion!

Posted-In: Brean Jonathan AschoffAnalyst Color Contracts Reiteration FDA Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com